Cathepsin L is crucial for the development of early experimental diabetic nephropathy

Kidney International

Volumn 90, Issue 5, 2016, Pages 1012-1022

  Garsen, Marjolein ^a   Rops, Angelique L W M M ^a   Dijkman, Henry ^a   Willemsen, Brigith ^a   van Kuppevelt, Toin H ^a   Russel, Frans G ^a   Rabelink, Ton J ^b   Berden, Jo H M ^a   Reinheckel, Thomas ^c   van der Vlag, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

diabetic nephropathy; glomerulus; proteinuria

Indexed keywords

CATHEPSIN L; HEPARANASE; SYNAPTOPODIN; ACTIN BINDING PROTEIN; BETA GLUCURONIDASE; CD2-ASSOCIATED PROTEIN; CYTOSKELETON PROTEIN; DYNAMIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SYNPO PROTEIN, MOUSE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; ENZYME ACTIVATION; EXPERIMENTAL DIABETIC NEPHROPATHY; FIBROSING ALVEOLITIS; KIDNEY FUNCTION; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; C57BL MOUSE; COMPLICATION; DIABETIC NEPHROPATHIES; EXPERIMENTAL DIABETES MELLITUS; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CATHEPSIN L; CYTOSKELETAL PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DYNAMINS; GLUCURONIDASE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS;

EID: 84994076693     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.06.035     Document Type: Article

References (63)

1. 1 Ritz, E., Rychlik, I., Locatelli, F., Halimi, S., End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 34 (1999), 795–808.
2. 2 Gilbertson, D.T., Liu, J., Xue, J.L., et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16 (2005), 3736–3741.
3. 3 Tryggvason, K., Pettersson, E., Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Int Med 254 (2003), 216–224.
4. 4 Patrakka, J., Tryggvason, K., Molecular make-up of the glomerular filtration barrier. Biochem Biophys Res Commun 396 (2010), 164–169.
5. 5 Garsen, M., Rops, A.L., Rabelink, T.J., et al. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant 29 (2014), 49–55.
6. 6 Yang, M., Zhang, Y., Pan, J., et al. Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol 9 (2007), 970–977.
7. 7 Roth, W., Deussing, J., Botchkarev, V.A., et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 14 (2000), 2075–2086.
8. 8 Potts, W., Bowyer, J., Jones, H., et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int JExp Pathol 85 (2004), 85–96.
9. 9 Honey, K., Nakagawa, T., Peters, C., Rudensky, A., Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J Exp Med 195 (2002), 1349–1358.
10. 10 Sever, S., Altintas, M.M., Nankoe, S.R., et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 117 (2007), 2095–2104.
11. 11 Reiser, J., Oh, J., Shirato, I., et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279 (2004), 34827–34832.
12. 12 Baricos, W.H., Cortez, S.L., Le, Q.C., et al. Evidence suggesting a role for cathepsin L in an experimental model of glomerulonephritis. Arch Biochem Biophys 288 (1991), 468–472.
13. 13 Faul, C., Donnelly, M., Merscher-Gomez, S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14 (2008), 931–938.
14. 14 Yaddanapudi, S., Altintas, M.M., Kistler, A.D., et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest 121 (2011), 3965–3980.
15. 15 Kim, J.M., Wu, H., Green, G., et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300 (2003), 1298–1300.
16. 16 Huber, T.B., Kwoh, C., Wu, H., et al. Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest 116 (2006), 1337–1345.
17. 17 Lehtonen, S., Zhao, F., Lehtonen, E., CD2-associated protein directly interacts with the actin cytoskeleton. Am J Physiol Renal Physiol 283 (2002), F734–F743.
18. 18 Mundel, P., Reiser, J., Proteinuria: an enzymatic disease of the podocyte?. Kidney Int 77 (2010), 571–580.
19. 19 Reiser, J., Adair, B., Reinheckel, T., Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120 (2010), 3421–3431.
20. 20 Bernfield, M., Gotte, M., Park, P.W., et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68 (1999), 729–777.
21. 21 Rops, A.L., van der Vlag, J., Lensen, J.F., et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 65 (2004), 768–785.
22. 22 van den Born, J., van den Heuvel, L.P., Bakker, M.A., et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43 (1993), 454–463.
23. 23 van den Hoven, M.J., Rops, A.L., Vlodavsky, I., et al. Heparanase in glomerular diseases. Kidney Int 72 (2007), 543–548.
24. 24 Abboud-Jarrous, G., Atzmon, R., Peretz, T., et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283 (2008), 18167–18176.
25. 25 Gil, N., Goldberg, R., Neuman, T., et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61 (2012), 208–216.
26. 26 Goldberg, R., Rubinstein, A.M., Gil, N., et al. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes 63 (2014), 4302–4313.
27. 27 Breyer, M.D., Bottinger, E., Brosius, F.C. 3rd, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16 (2005), 27–45.
28. 28 Ziyadeh, F.N., Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 15:Suppl 1 (2004), S55–S57.
29. 29 Yamamoto, T., Noble, N.A., Miller, D.E., Border, W.A., Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45 (1994), 916–927.
30. 30 Wang, S., Denichilo, M., Brubaker, C., Hirschberg, R., Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60 (2001), 96–105.
31. 31 Tesch, G.H., Macrophages and diabetic nephropathy. Semin Nephrol 30 (2010), 290–301.
32. 32 Maehr, R., Mintern, J.D., Herman, A.E., et al. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J Clin Invest 115 (2005), 2934–2943.
33. 33 Schnedl, W.J., Ferber, S., Johnson, J.H., Newgard, C.B., STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43 (1994), 1326–1333.
34. 34 Kroncke, K.D., Fehsel, K., Sommer, A., et al. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem Hoppe Seyler 376 (1995), 179–185.
35. 35 Yamamoto, H., Uchigata, Y., Okamoto, H., Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294 (1981), 284–286.
36. 36 Basi, S., Fesler, P., Mimran, A., Lewis, J.B., Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?. Diabetes Care 31:Suppl 2 (2008), S194–S201.
37. 37 Moriya, T., Tanaka, S., Kawasaki, R., et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care 36 (2013), 2803–2809.
38. 38 Bruno, G., Merletti, F., Biggeri, A., et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26 (2003), 2150–2155.
39. 39 Rossing, P., Hougaard, P., Parving, H.H., Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 68 (2005), 1446–1450.
40. 40 Kistler, A.D., Peev, V., Forst, A.L., et al. Enzymatic disease of the podocyte. Pediatr Nephrol 25 (2010), 1017–1023.
41. 41 Kalluri, R., Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 17 (2006), 2383–2389.
42. –/– mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 116 (2006), 2272–2279.
43. 43 Topham, P.S., Kawachi, H., Haydar, S.A., et al. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest 104 (1999), 1559–1566.
44. 44 van den Berg, J.G., van den Bergh Weerman, M.A., Assmann, K.J., et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 66 (2004), 1901–1906.
45. 45 Masola, V., Zaza, G., Secchi, M.F., et al. Heparanase is a key player in renal fibrosis by regulating TGF-beta expression and activity. Biochim Biophys Acta 1843 (2014), 2122–2128.
46. 46 Masola, V., Zaza, G., Onisto, M., et al. Impact of heparanase on renal fibrosis. J Transl Med, 13, 2015, 181.
47. 47 Ko, G.J., Boo, C.S., Jo, S.K., et al. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 23 (2008), 842–852.
48. 48 Chow, F.Y., Nikolic-Paterson, D.J., Atkins, R.C., et al. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 19 (2004), 2987–2996.
49. 49 Singh, A., Satchell, S.C., Neal, C.R., et al. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 18 (2007), 2885–2893.
50. 50 Salmon, A.H., Ferguson, J.K., Burford, J.L., et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 23 (2012), 1339–1350.
51. 51 Garsen M, Lenoir O, Rops AL, et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx [e-pub ahead of print]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2015091070. Accessed June 22, 2016.
52. 52 Chen, S., Wassenhove-McCarthy, D., Yamaguchi, Y., et al. Podocytes require the engagement of cell surface heparan sulfate proteoglycans for adhesion to extracellular matrices. Kidney Int 78 (2010), 1088–1099.
53. 53 Chen, S., Wassenhove-McCarthy, D.J., Yamaguchi, Y., et al. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 74 (2008), 289–299.
54. 54 Garsen, M., Benner, M., Dijkman, H.B., et al. Heparanase is essential for the development of acute experimental glomerulonephritis. Am J Pathol 186 (2016), 805–815.
55. 55 Kramer, A., van den Hoven, M., Rops, A., et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 17 (2006), 2513–2520.
56. 56 Garsen, M., Sonneveld, R., Rops, A.L., et al. Vitamin D attenuates proteinuria by inhibition of heparanase expression in the podocyte. J Pathol 237 (2015), 472–481.
57. 57 Wyczalkowska-Tomasik, A., Bartlomiejczyk, I., Gornicka, B., Paczek, L., Strong association between fibronectin accumulation and lowered cathepsin B activity in glomeruli of diabetic rats. J Physiol Pharmacol 63 (2012), 525–530.
58. 58 Kumar Vr, S., Darisipudi, M.N., Steiger, S., et al. Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications. J Am Soc Nephrol 27 (2016), 1635–1649.
59. 59 Dunn, S.R., Qi, Z., Bottinger, E.P., et al. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 65 (2004), 1959–1967.
60. 60 Rops, A.L., Gotte, M., Baselmans, M.H., et al. Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int 72 (2007), 1204–1215.
61. 61 van Kuppevelt, T.H., Dennissen, M.A., van Venrooij, W.J., et al. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273 (1998), 12960–12966.
62. 62 Raats, C.J., Bakker, M.A., Hoch, W., et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 273 (1998), 17832–17838.
63. 63 Oba, S., Kumano, S., Suzuki, E., et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One, 5, 2010, e13614.